Corcept Therapeutics Inc. (CORT), Monday announced data from its Phase 3 long-term extension study, evaluating relacorilant in patients with endogenous hypercortisolism, which is caused by excessive activity of the hormone cortisol.
The findings showed that patients treated with relacorilant experienced clinically meaningful and durable cardiometabolic improvements. It was well-tolerated, with a treatment duration of up to six years.
Moreover, the participants experienced improvement in blood pressure while maintaining response in other cardiometabolic measures, such as glycemic control and body weight.
Currently, Corcept's stock is trading at $54.95, down 0.81 percent on the Nasdaq.
For comments and feedback contact: editorial@rttnews.com
Health News
May 01, 2026 15:54 ET Central banks dominated the economics news flow this week with almost all major ones announcing their latest policy decisions and many boosted expectations for a rate hike in June. In other news, several countries released the preliminary data for first quarter economic growth. In the U.S., comments by Fed Chair Jerome Powell were also in focus as his term ends this month.